The dispute started in November when Takeda (TAK) alleged that Scilex (SCLX) infringed its patents related to its colchicine product, Colcrys, when the company sought FDA approval to market its ...

filed by Granules Pharmaceuticals Inc for Colchicine capsules in the strength of 0.6 mg, Granules India said in a filing to the BSE. The company's product is a generic version of Hikma ...